diamyd Medical Advances Type 1 Diabetes Immunotherapy with DIAGNODE-3 Trial Focused on HLA DR3-DQ2 Genotype
Stockholm, Sweden – December 4, 2025 – Diamyd Medical AB today announced progress in its antigen-specific immunotherapy program for type 1 diabetes, highlighted by the ongoing DIAGNODE-3 trial. The trial is specifically designed for individuals carrying the HLA DR3-DQ2 genotype, a common genetic marker present in approximately 40% of those with type 1 diabetes in both Europe and the United States. This focused approach builds upon previous positive findings demonstrated in a large,genetically predefined cohort and a European Phase IIb trial.
Diamyd’s immunotherapy, Diamyd®, utilizes recombinant GAD65 protein to target the autoimmune response underlying type 1 diabetes. The company is actively developing a dedicated biomanufacturing facility in Umeå, Sweden, to support the production of this key ingredient. This strategic investment aims to ensure a reliable supply for clinical trials and potential future commercialization. The focused DIAGNODE-3 trial and expanded manufacturing capacity represent a significant step forward in Diamyd Medical’s efforts to develop a disease-modifying therapy for individuals with early-stage type 1 diabetes.
Diamyd Medical holds investments in NextCell Pharma AB, a stem cell company, and mainlyai AB, an artificial intelligence firm. The company’s B shares are listed on Nasdaq First north Growth Market under the ticker DMYD B, with FNCA Sweden AB serving as its Certified adviser.
Contact:
Ulf hannelius, CEO, ulf.hannelius@diamyd.com
Niklas Axelsson, CFO, niklas.axelsson@diamyd.com
Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden. phone: +46 8 661 00 26
Email: info@diamyd.com. Reg. no.: 556242-3797.Website: https://www.diamyd.com